Overview

Zalutumumab in Non-curable Patients With SCCHN

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Treatment, In combination with BSC, Open-label, Single arm, Efficacy Study.
Phase:
Phase 2
Details
Lead Sponsor:
Genmab
Treatments:
Antibodies, Monoclonal
Zalutumumab